# Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients

Study · id `cardio:ct-nct01325935` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01325935](<https://clinicaltrials.gov/study/NCT01325935>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01325935

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1187 participants.

## Technical summary

Registry record NCT01325935. Non-randomized; no masking; primary purpose treatment. Start 2011-04 (registry gives no type); primary completion 2013-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1187 participants (enrolled count; ClinicalTrials.gov record NCT01325935, source copy `cardio:ctgov-nct01325935-2016-01-07`, retrieved 2026-10-26)
- Start date: 2011-04 (registry gives no type) (ClinicalTrials.gov record NCT01325935, source copy `cardio:ctgov-nct01325935-2016-01-07`, retrieved 2026-10-26)
- Primary completion: 2013-09 (actual) (ClinicalTrials.gov record NCT01325935, source copy `cardio:ctgov-nct01325935-2016-01-07`, retrieved 2026-10-26)
- Completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01325935, source copy `cardio:ctgov-nct01325935-2016-01-07`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01325935, source copy `cardio:ctgov-nct01325935-2016-01-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01325935-2016-01-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients
- Acronym: OPERA
- Condition: Coronary Artery Disease
- Intervention (Drug): Clopidogrel
- Lead sponsor: Associations for Establishment of Evidence in Interventions
- Lead sponsor class: OTHER
- Collaborator: Medtronic
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- Registry lists this organization as a collaborator: Medtronic (`cardio:medtronic`)

## Provenance

Content hash: 103124797d116dc712f02261ced0aa9c2659f32838e72d133c7f27770256af07
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
